Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report) was the target of a significant decline in short interest in February. As of February 29th, there was short interest totalling 21,070,000 shares, a decline of 10.0% from the February 14th total of 23,410,000 shares. Based on an average trading volume of 4,260,000 shares, the days-to-cover ratio is presently 4.9 days.
Institutional Investors Weigh In On Lexicon Pharmaceuticals
Several hedge funds have recently added to or reduced their stakes in LXRX. Swiss National Bank boosted its holdings in Lexicon Pharmaceuticals by 10.6% in the first quarter. Swiss National Bank now owns 140,800 shares of the biopharmaceutical company’s stock worth $294,000 after acquiring an additional 13,500 shares in the last quarter. Bank of Montreal Can bought a new position in shares of Lexicon Pharmaceuticals during the first quarter valued at $26,000. Dimensional Fund Advisors LP lifted its holdings in shares of Lexicon Pharmaceuticals by 12.5% during the first quarter. Dimensional Fund Advisors LP now owns 869,611 shares of the biopharmaceutical company’s stock valued at $1,818,000 after purchasing an additional 96,633 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Lexicon Pharmaceuticals by 2.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 501,128 shares of the biopharmaceutical company’s stock valued at $1,048,000 after purchasing an additional 12,710 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Lexicon Pharmaceuticals during the first quarter valued at $186,000.
Lexicon Pharmaceuticals Stock Up 7.0 %
Lexicon Pharmaceuticals stock traded up $0.17 during mid-day trading on Friday, hitting $2.60. The company had a trading volume of 7,482,849 shares, compared to its average volume of 5,069,103. The company has a current ratio of 6.92, a quick ratio of 6.91 and a debt-to-equity ratio of 0.71. The stock’s 50 day moving average price is $2.17 and its two-hundred day moving average price is $1.58. Lexicon Pharmaceuticals has a 12 month low of $0.92 and a 12 month high of $3.79. The company has a market capitalization of $636.82 million, a PE ratio of -3.25 and a beta of 1.28.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.